White House’s $215M precision medicine initiative ushers in new era in healthcare

Laura Pedulli | | Health Exec | Policy & Regulations

The White House announced that it is pumping $215 million into federal health and science agencies so they can develop infrastructure that allows data to flow between medical clinics to labs that sequence the human genome and gather other data, reports Politico.

The Precision Medicine Initiative, first mentioned in President Obama’s State of the Union Address, ultimately seeks to find more targeted personalized approaches to treatments and cures, according to the story.

Read more below:

Obama’s ‘precision medicine’ initiative could bring insight into disease

Laura Pedulli

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.